Sveriges mest populära poddar
Future of Drug Discovery

Björn Schimmöller - Inorganic Chemistry at the Frontier of Immunotherapy (FODD #15)

22 min17 januari 2024

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.

Host: ⁠⁠Murat Tunaboylu⁠⁠, Co-Founder and CEO of Antiverse.

You will learn:

  • The founding journey of iuvantium from Oxford University.
  • How Iuvantium is enhancing immune system efficiency and reducing clinical trial uncertainty using inorganic chemistry.
  • ‘Decoding’ the immune system and how personalised medicine may lead to the next leaps in immunotherapy.

Things mentioned:

Additional Materials:

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.antiverse.io⁠⁠

Never miss a future event!

We'll notify you when a new event is scheduled. Fill out ⁠⁠⁠⁠⁠⁠this form⁠⁠⁠⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

Fler avsnitt av Future of Drug Discovery

Visa alla avsnitt av Future of Drug Discovery

Future of Drug Discovery med Murat Tunaboylu finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.